BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented ...
Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...
Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...
At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results